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Abstract
Purpose Prolonged propofol infusion induces skeletal muscle damage. However, it is well known that the lipid emulsion 
that is the solvent of propofol causes various types of tissue damage via lipid peroxidation, and that propofol, conversely, 
has an anti-lipid peroxidative effect. The purpose of this study was to determine whether propofol or the lipid emulsion is 
the cause of muscle damage following prolonged administration.
Methods Rats were divided into four groups: NI group (no intervention), Cath group (venous catheter insertion only), Prop 
group (1% propofol (Maruishi) intravenous infusion at 10 mg/kg/h), and Lipid group (10% Lipofundin® intravenous infu-
sion at 100 mg/kg/h) (n = 10, each group). 1% Propofol (Maruishi) or Lipofundin was infused at 1 mL/kg/h for 72 h. The 
solvent of 1% propofol (Maruishi) is a 10% lipid emulsion. Lipofundin consists of 50% long-chain triacylglycerols and 50% 
medium-chain triacylglycerols, similar to the propofol solvent. Plasma concentrations of creatine kinase and myoglobin, 
superoxide production level, and 4-hydroxynonenal and malondialdehyde expression in the gastrocnemius muscle were 
evaluated 72 h after the interventions.
Results Plasma concentrations of creatine kinase and myoglobin in the Lipid group were significantly higher than those in 
the other three groups. The superoxide production level, and 4-hydroxynonenal and malondialdehyde expression in the Lipid 
group were also significantly higher than in the other three groups.
Conclusion Lipofundin induces skeletal muscle damage via lipid peroxidation, and 1% propofol (Maruishi) conversely sup-
presses the muscle damage via antioxidant effects.
Keywords Propofol · Lipid peroxidation · Intravenous fat emulsions · Antioxidants
Introduction
Propofol is a short-acting intravenous anesthetic that is fre-
quently used as a sedative for patients receiving anesthesia 
and in intensive care units. Since it has high lipophilicity, 
propofol is dissolved in a lipid emulsion in clinical settings. 
However, it is well known that a high dose and prolonged 
duration of propofol infusion induce skeletal muscle dam-
age [1, 2]. The mechanism of propofol-induced muscle 
damage is thought to be related to mitochondrial dysfunc-
tion, especially in the electron transport system on the inner 
mitochondrial membrane [3–5]. However, the details of the 
mechanism have not been clearly elucidated. Moreover, 
most studies investigated the effect of propofol itself, and 
the effect of the lipid emulsion that is the solvent of propofol 
has not been examined.
Similar to propofol, high doses of a lipid emulsion can 
also cause various types of tissue damage, including of the 
skeletal muscle [6]. Lipid emulsions contain large amounts 
of polyunsaturated fatty acids, such as soybean oil. In an 
in vivo experiment, intravenous administration of polyun-
saturated fatty acids induced lipid peroxidation, which is 
a type of oxidative stress, in various types of tissues [7]. 
Lipid peroxidation is a self-promoting chain reaction target-
ing polyunsaturated fatty acids in cellular membranes that 
changes membrane properties and the function of membrane 
proteins; furthermore, the end-products of lipid peroxidation 
function as toxic second messengers, inducing apoptosis and 
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necrosis [8, 9]. Some antioxidants can inhibit lipid peroxi-
dation by acting as free radical scavengers, resulting in the 
formation of non-radical products [10]. It is also well known 
that propofol itself has antioxidant effects, especially on lipid 
peroxidation [11, 12].
The purpose of this study was to determine whether it is 
propofol or its lipid emulsion vehicle that is the cause of the 
skeletal muscle damage resulting from prolonged infusion 
of the commercially available propofol formulation. For this, 
the effects of prolonged intravenous infusion of lipid emul-
sion and propofol on skeletal muscle were evaluated using 
a rat model.
Methods
This manuscript was written in accordance with Enhancing 
the QUAlity and Transparency Of health Research (EQUA-
TOR) guidelines.
Animals and instrumentation
The protocol of this study was approved by the Ethics 
Committee (approval code: 15-046) for Animals of Sap-
poro Medical University School of Medicine. This animal 
experiment complied with the Animal Research: Reporting 
of In Vivo Experiments (ARRIVE) guidelines and adhered 
to the guidelines for proper conduct of animal experiments 
issued by both the Japanese Ministry of Education, Culture, 
Sports, Science and Technology and the Japanese Minis-
try of Health, Labour and Welfare, and also by the Science 
Council of Japan. Male Wistar rats (150–200 g) were kept at 
22–24 °C with a 12-h light–dark cycle. Ad libitum access to 
food and water was provided. In all the animals, a disposable 
sterile intravenous catheter was inserted into the left femoral 
vein under anesthesia with 3% sevoflurane. The free end of 
the catheter was tunneled through the subcutaneous tissue 
from the left femoral site to the center of the rats’ back. To 
prevent the rats from biting the catheter, the free end in the 
back was then passed into a stainless-steel coil. A syringe 
pump  (Terufusion® infusion pump; Terumo, Tokyo, Japan) 
was used for drug infusion. During infusion, each rat was 
isolated in a separate cage and given free access to food and 
water, as before catheterization. Moreover, all rats, including 
those who received propofol, were able to breath spontane-
ously without any airway maintenance.
Experimental protocol
Forty rats were randomly divided into the NI group (no 
intervention), Cath group (venous catheterization only), 
Prop group (receiving 1% propofol (Maruishi, Osaka, Japan) 
infusion at 10 mg/kg/h), and Lipid group (receiving 10% 
Lipofundin (B. Braun, Melsungen, Germany) infusion at 
100 mg/kg/h) (n = 10, each group); in the Prop and Lipid 
groups, 1% propofol (Maruishi) or Lipofundin, respectively, 
was infused at 1 mL/kg/h for 72 h. The solvent of 1% propo-
fol (Maruishi) is a 10% lipid emulsion. The infusion rate of 
1% propofol was determined based on the results of prelimi-
nary experiments, such that the level of sedation in the rats 
which received a 20 mg/kg/h propofol infusion was too deep 
to ingest food or water, inducing circulatory collapse and 
death within 24 h of the start of infusion. The rats need to be 
able to ingest food and water freely to prevent caloric deple-
tion and dehydration. Thus, 10 mg/kg/h infusion rate of 1% 
propofol, a dosage not sufficient to induce sedation in rats, 
was applied in the Prop group. Since Lipofundin consists of 
50% long-chain triacylglycerols and 50% medium-chain tria-
cylglycerols, it has a similar composition as the solvent used 
in the commercially available propofol preparation. After 
drug infusion for 72 h, the rats were re-anesthetized with 
3% sevoflurane for collection of blood and skeletal muscle 
samples. The blood samples were collected from the left 
ventricle of the heart immediately after anesthetic induction. 
The collected blood samples were centrifuged at 12,000g 
for 10 min to extract the plasma, which was subsequently 
stored at − 80 °C for enzyme-linked immunosorbent assay 
and enzymatic assay. Gastrocnemius muscle samples of the 
right hind limb were used for measurement of superoxide 
production, fixed with 10% formaldehyde solution for immu-
nohistochemistry, and stored at − 80 °C for Western blot 
analysis.
Evaluation of level of consciousness
The consciousness level of each group was evaluated in 
accordance with the methods of the previous studies [13, 
14]. To strictly evaluate the status of consciousness/sedation 
of the rats during drug infusion, two methods were used in 
the current study. In the first method, four parameters were 
assessed: the tail pinch reflex, pedal withdrawal reflex in 
the forelimbs, pedal withdrawal reflex in the hindlimbs, and 
corneal reflex. When a reflex reaction to stimulation was 
observed, the score was recorded as zero. In contrast, when 
no reflex reaction was observed, the score was recorded as 
one. The total score of the four reflex tests was calculated, 
and a score of three or more was considered to indicate that 
the animal was deeply sedated. A score of zero indicated 
that the rats were awake, and could spontaneously ingest 
the ad  libitum available food and water. In the second 
method, two parameters were used to assess consciousness: 
the toe pinch test and righting reflex. In these two tests, the 
responses were scored on a scale of 1–5 (1: deeply sedated, 
5: not sedated). All evaluations of consciousness were per-
formed at 2, 24, 48, and 72 h after the initiation of drug 
infusion.
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Enzyme‑linked immunosorbent assay
The plasma concentration of myoglobin was determined in 
20 μL of plasma using the rat myoglobin ELISA kit (Life 
Diagnostic Inc., West Chester, PA) according to the manu-
facturer’s instructions. Data were collected spectrophotomet-
rically using a standard 96-well plate reader at a wavelength 
of 450 nm (Sunrise™ reader, Tecan Group Ltd., Männedorf, 
Switzerland).
Enzymatic assay
Plasma concentrations of creatine kinase (CK) were meas-
ured in 5 μL of plasma using a Cicali CK Kit (Kanto Chemi-
cal Co., Inc., Tokyo, Japan) according to the manufacturer’s 
instructions. Data were collected spectrophotometrically 
using a Beckman Coulter AU5400 chemistry analyzer 
(Beckman Coulter Inc., Brea, CA).
Western blotting
Total protein was extracted with ice-cold buffer from a 
stored skeletal muscle sample [15], and the concentrations 
of protein were determined with a BCA Protein Assay Kit 
(Thermo Fisher Scientific, Waltham, MA). Data of protein 
concentrations were collected spectrophotometrically by 
GENESYS 10S UV–Vis™ (Thermo Fisher Scientific) at a 
wavelength of 562 nm. Briefly, equal amounts of proteins 
were separated by 7.5% sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis (SDS-PAGE) and transferred to a 
polyvinylidene fluoride membrane (Thermo Fisher Scien-
tific) after hydrophilization using 100% methanol. Mem-
branes were probed to antibodies against malondialdehyde 
(MDA) (STA-032, 1:1000; Cell Biolabs, Cambridge, UK) 
and β-actin (#4967, 1:1000; Cell Signaling Technology, 
Beverly, MA). The 64-kDa band was used for quantita-
tive evaluation of MDA according to the manufacturer’s 
instructions. Following protein quantification, protein den-
sities were normalized to internal standards on each gel, and 
expressed relative to β-actin. The internal standard used was 
an untreated rat gastrocnemius muscle that underwent the 
same assessment protocol mentioned above. The blots were 
then analyzed blindly.
Immunohistochemistry
After extraction of skeletal muscle, the samples were fixed 
with 10% formaldehyde. Paraffin-embedded skeletal muscle 
tissue was cut into 3-μm-thick slices. After deparaffiniza-
tion followed by blocking with 3% hydrogen peroxide and 
4% BLOCK ACE (DS Pharma Biomedical, Osaka, Japan), 
the slices were incubated with primary antibodies against 
4-hydroxynonenal (4-HNE) (ab46545, 1:400; Abcam PLC, 
Cambridge, UK) for 60 min at room temperature. The sec-
tions were incubated with Histofine Simple Stain MAX-PO 
(Nichirei Biosciences, Tokyo, Japan) for rats. Visualization 
with diaminobenzidine substrate (Bond Polymer Refine 
Detection; Leica Biosystems, Wetzlar, Germany) was fol-
lowed by counterstaining with Mayer’s hematoxylin (Bond 
Polymer Refine Detection; Leica Biosystems). Images were 
obtained with a BZ9000 fluorescence microscope (Keyence 
Corp., Osaka, Japan). Five images were randomly captured 
for each specimen and analyzed using the Image J program 
with Color Deconvolution plugin for calculating optical 
density. A previously described procedure was followed to 
perform optical density calculations [16, 17].
Measurements of superoxide production
The oxidative fluorescent dye, dihydroethidium (Thermo 
Fisher Scientific), was used to evaluate levels of superoxide 
in situ, as described previously [18]. Skeletal muscle cells 
are permeable to dihydroethidium, and dihydroethidium is 
oxidized to fluorescent ethidium bromide by superoxide. 
Dihydroethidium is known to be a specific fluorescent probe 
for superoxide detection [19]. Unfixed frozen skeletal mus-
cle samples were sliced into 20-μm-thick slices at − 20 °C 
and placed on glass slides. Dihydroethidium (2 × 10–6 M) 
in phosphate-buffered saline (pH = 7.4) was applied to each 
sliced sample. The slices were incubated in a light-protected 
chamber at 37 °C for 20 min. Images were obtained with a 
ConfoCol3LSM5 10META (ZEISS, Oberkochen, Germany) 
laser scanning microscope equipped with a DPSS laser. 
Fluorescence was detected with a 561-nm long-pass filter. 
The laser settings were identical for acquisition of images 
from all slices. Five images were randomly captured for each 
specimen. Captured images were analyzed with the Image J 
program, and the data were expressed as percentages of the 
positive areas presented in the field.
Statistical analysis
Serum concentrations of CK and myoglobin, the expression 
level of 4-HNE and MDA, and the superoxide production 
level were statistically analyzed by one-way analysis of 
variance followed by Tukey’s post hoc test. Normality and 
equal variance of data among all the groups were confirmed 
by the Shapiro–Wilk test and F test, respectively. Data are 
presented as means ± standard deviations. All statistical 
analyses were performed with GraphPad Prism 7.0 software 
(GraphPad software, La Jolla, CA). A two-tailed p value 
< 0.05 was considered statistically significant.
Sample size was calculated with the G*power 3.1 statis-
tical power analysis program (Heinrich-Heine-University, 
Düsseldorf, Germany). According to a previous report, 
a standard deviation of 37.5 U/L and mean difference of 
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57.9 U/L in CK are indicative of a clinically meaningful 
difference in CK [20]. As a result, n = 10 in each group was 
considered an adequate sample size, assuming a statistical 
power of 0.9 at a two-tailed significance level of 0.05.
Results
Level of consciousness
Reportedly, a propofol infusion of 44–55 mg/kg/h is required 
for maintenance of anesthesia in rats [21]. To confirm that 
the rats were not sedated during the 10 mg/kg/h propofol 
infusion, their consciousness level was evaluated. The total 
scores of all four parameters were zero and the scores of the 
additional two tests were five at the four evaluation timings 
in each group. The results indicate that the dose of propofol 
used in the Prop group did not reach the dose needed for rat 
sedation. Additionally, all rats were spontaneously breathing 
and survived during the 72 h of drug infusion.
Evaluation of skeletal muscle damage
Plasma concentration of CK in the Lipid group was sig-
nificantly higher than that in the other three groups (Lipid 
489 ± 99 U/L; NI 251 ± 84 [95% CI 126–349] U/L; Cath 
284 ± 75 [95% CI 93–316] U/L; Prop 306 ± 109 [95% CI 
71–295] U/L, p < 0.001 for all). There were no signifi-
cant differences between the NI, Cath, and Prop groups 
(Fig. 1a). Similarly, the plasma concentration of myoglobin 
was also significantly higher in the Lipid group than in the 
other three groups (Lipid 480 ± 193 ng/mL; NI 109 ± 103 
[95% CI 114–466] ng/mL, p < 0.001; Cath 193 ± 99 [95% 
CI 111–463] ng/mL, p < 0.001; Prop 236 ± 166 [95% CI 
68–420] ng/mL, p = 0.004). There were no statistically 
significant differences between the NI, Cath, and Prop 
groups (Fig. 1b).
Superoxide production in lipid peroxidation
Since superoxide is recognized as an intermediate product 
in lipid peroxidation [19], superoxide production in skeletal 
muscle was measured using dihydroethidium in this study. 
Superoxide production was significantly higher in the Lipid 
group than in the other three groups (Lipid 2.74 ± 0.86; NI 
1.05 ± 0.17 [95% CI 0.65–2.73], p = 0.001; Cath 1.03 ± 0.49 
[95% CI 0.67–2.75], p = 0.001; Prop 1.40 ± 0.56 [95% CI 
0.30–2.39], p = 0.010). There were no statistically significant 
differences in the other three groups. Quantitative evalua-
tions of superoxide production and representative images 
for each group are presented in Fig. 2.
Progression of lipid peroxidation in skeletal muscle
To investigate the progression of lipid peroxidation with 
lipid infusion, expression of 4-HNE and MDA, which are 
the end products and markers of lipid peroxidation, were 
evaluated by immunohistochemistry and Western blotting, 
respectively. The results of immunohistochemistry showed 
that the expression level of 4-HNE was significantly higher 
in the Lipid group than in the other three groups (Lipid 
1.36 ± 0.30; NI 1.00 ± 0.11 [95% CI 0.06–0.65], p = 0.017; 
Cath 1.01 ± 0.02 [95% CI 0.05–0.64], p = 0.019; Prop 
1.03 ± 0.08 [95% CI 0.04–0.61], p = 0.021, Fig. 3a, b). Fur-
thermore, the expression level of MDA was significantly 
higher in the Lipid group than in the other three groups 
(Lipid 1.77 ± 0.25; NI 0.97 ± 0.11 [95% CI 0.30–1.30], 
p = 0.010; Cath 1.03 ± 0.13 [95% CI 0.25–1.22], p = 0.012; 
Prop 1.04 ± 0.27 [95% CI 0.03–1.44], p = 0.043, Fig. 3c). 
Fig. 1  Evaluation of skeletal muscle damage by measuring plasma 
concentrations of muscle enzymes. a Lipid infusion induced elevation 
of plasma creatine kinase levels. *p < 0.001 compared to each of the 
other three groups. b Lipid infusion induced an elevation of plasma 
myoglobin levels. *p < 0.001 compared to NI and Cath groups, 
respectively; †p = 0.004 compared to the Prop group. The data are 
presented as means and standard deviations (n = 10)
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Fig. 2  Superoxide production in skeletal muscle detected using dihy-
droethidium. a Representative images of superoxide production in NI, 
Cath, Prop, and Lipid groups. b Quantitative evaluation of superox-
ide production. *p = 0.001 versus NI and Cath groups, respectively; 
†p = 0.010 versus the Prop group. The data are presented as means 
and standard deviations (n = 5)
Fig. 3  Progression of lipid peroxidation in skeletal muscle. a Repre-
sentative images of immunohistochemistry evaluation of 4-hydrox-
ynonenal in the gastrocnemius muscle. The brown area indicates 
4-hydroxynonenal stained by diaminobenzidine. The expression level 
of 4-hydroxynonenal was higher in the Lipid group than in the other 
three groups. b Quantitative evaluation of the expression level of 
4-hydroxynonenal. *p = 0.017 versus the NI group. †p = 0.019 versus 
the Cath group. #p = 0.021 versus the Prop group. c Representative 
immunoblot images and the corresponding analysis of the expres-
sion of malondialdehyde by Western blotting. *p = 0.010 versus the 
NI group. †p = 0.012 versus the Cath group. #p = 0.043 versus the 
Prop group. The data are presented as means and standard deviations 
(n = 5–6). MDA malondialdehyde
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These results suggest that lipid infusion causes progressive 
lipid peroxidation in skeletal muscle.
Discussion
The main findings of this animal study are that lipid emul-
sion induces skeletal muscle damage via lipid peroxidation, 
whereas propofol attenuates lipid-induced skeletal muscle 
damage.
Lipid peroxidation is a self-promoting chain reaction, in 
which oxidants attack polyunsaturated fatty acids, result-
ing in the generation of lipid peroxyl radicals and hydrop-
eroxides, as described previously [9]. Hydroxy radicals and 
hydroperoxides mainly affect polyunsaturated fatty acids and 
act as initiators of lipid peroxidation, resulting in the chain 
reaction. Lipid peroxidation is also induced by intravenous 
administration of soybean oil-based lipid emulsion, which is 
rich in polyunsaturated fatty acids [22]. The main end prod-
ucts of lipid peroxidation are MDA and 4-HNE. Both are 
reliable markers of lipid peroxidation and are considered as 
toxic second messengers regulating various gene transcrip-
tions and affecting cell proliferation, differentiation, apop-
tosis, and necrosis [9]. In the present study, lipid infusion 
induced relatively high expressions of MDA and 4-HNE in 
skeletal muscle, suggesting that the mechanism of skeletal 
muscle damage involves lipid peroxidation.
Lipid peroxidation can be terminated by antioxidants. 
Many studies reported that propofol has antioxidant effects 
and, in particular, inhibits the lipid peroxidation reaction 
[11, 23, 24]. Propofol has a similar structure as butylated 
hydroxytoluene, which is known to be a free radical scav-
enger, and the anti-lipid peroxidation effect of propofol is 
larger than that of butylated hydroxytoluene [25]. It is pos-
sible that this strong antioxidant effect of propofol contrib-
uted to attenuation of the progression of lipid peroxidation 
and skeletal muscle damage in the Prop group in this study.
The propofol infusion rate in the Prop group in the pre-
sent study was 10 mg/kg/h for 72 h. Bray reported that there 
was a strong correlation between skeletal muscle damage 
and a propofol infusion of 4 mg/kg/h given for longer than 
48 h in a clinical setting [1]. To ensure that the rats sur-
vived for more than 48 h, it was necessary for the rats to 
have free access to water and food and to remain conscious, 
because management of respiration, circulation, and nutri-
tion is extremely difficult in the sedated state. The infusion 
rate of propofol for anesthetic maintenance is reportedly 
44–55 mg/kg/h [26]. Moreover, Schläpfer et al. used propo-
fol for rats and reported that the median infusion rate of 
propofol was 10.2 mg/kg/h [27]. In their study, rats who 
received propofol remained hemodynamically stable for 
24 h. On the basis of these results, the propofol infusion 
rate of 10 mg/kg/h for 72 h was used in the present study to 
achieve the long duration of propofol infusion.
This study has certain limitations. In the current study, 
Lipofundin was used in the Lipid group as the vehicle con-
trol of 1% propofol (Maruishi) according to the previous 
reports [28, 29]. Ideally, although a lipid emulsion that is 
identical to the vehicle of 1% propofol (Maruishi) should 
have been used in the Lipid group, we were unable to acquire 
this type of lipid emulsion. Lipofundin is clinically used as 
a vehicle for propofol in other countries and has the same 
LCT/MCT ratio (50:50) as the 1% propofol (Maruishi) 
vehicle. While the fatty acid content of Lipofundin is men-
tioned as linoleic acid 24–29 mg/mL and α-linolenic acid 
2.5–5.5 mg/mL in the manufacturer’s literature, the fatty 
acid content of the vehicle of 1% propofol (Maruishi) has 
not been clarified. Linoleic acid, which is one of the n-6 fatty 
acids, is involved in the inflammatory response and is a regu-
lator of inflammation. On the other hand, α-linolenic acid, 
which is an n-3 fatty acid, possesses many anti-inflammatory 
properties. These polyunsaturated fatty acids play important 
roles in the structure and function of membranes, and serve 
as substrates for mediators involved in inflammation and the 
immune response [30]. It is possible that the differences in 
fatty acid content between Lipofundin and the vehicle of 
1% propofol (Maruishi) might have influenced our results. 
However, previous research that investigated the effects of 
different intravenous lipid emulsions containing various 
percentages of linoleic acid and α-linolenic acid on labora-
tory and clinical outcomes in adult patients reported similar 
clinical safety profiles and absence of effect on inflammatory 
markers between various types of lipid emulsions, including 
a 50:50 mixture of MCTs and soybean oil [29]. Moreover, 
several studies that compared the effects of soybean oil and 
a 50:50 mixture of MCTs and soybean oil on immune func-
tion reported that there was no difference in immune func-
tion [30–32]. We believe that the in vivo effect of the differ-
ences in fatty acid contents between 1% propofol (Maruishi) 
vehicle and Lipofundin is only slight, thus validating our 
utilization of Lipofundin as a lipid vehicle control. Sec-
ond, plasma CK or myoglobin levels were not increased in 
rats receiving propofol, suggesting the possibility that the 
mechanism of skeletal muscle damage in the present study 
does not exactly reflect propofol-induced muscle damage. 
This study used healthy rats as the subjects, while clinically, 
propofol-induced muscle damage tends to occur in patients 
who have excessive oxidative stress or mitochondrial dys-
function, such as is seen in sepsis [32]. We believe that the 
antioxidant effect of propofol is sufficient to suppress lipid 
peroxidation in a healthy model, although this effect is insuf-
ficient under excessive oxidative stress, resulting in skeletal 
muscle damage. Moreover, we believe that the lipid emul-
sion should be considered as a possible cause of propofol-
induced muscle damage. The third limitation of this study is 
Journal of Anesthesia 
1 3
that hemodynamic parameters could not be evaluated during 
the drug infusion period, because the drug infusion system 
physically interfered with the measurement of hemodynamic 
status. According to a previous report, rats remained hemo-
dynamically stable during a 10 mg/kg/h propofol intravenous 
infusion [27]. Moreover, hemodynamic collapse would be 
associated with a decrease in level of consciousness of the 
rats. However, evaluation of the consciousness level of the 
rats in the current study indicated no deterioration in the 
consciousness level in any of the rats. Additionally, all rats 
survived during the 72 h of drug infusion. Thus, it seems 
that severe hypotension or bradycardia did not occur in this 
animal model.
In conclusion, the present findings suggest that a 72-h 
infusion of lipid emulsion induces skeletal muscle damage 
via lipid peroxidation, while propofol itself attenuates mus-
cle damage by its antioxidant effect in healthy adolescent 
rats. Further studies should be conducted to clarify whether 
the lipid emulsion contributes to skeletal muscle damage in 
clinical settings.
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